# SAFETY DATA SHEET

# Section 1. Identification of the substance/mixture and of the company/undertaking

## 1.1 Product Identifier

**Product Name:** Lupron Depot

Synonyms: Leuprolide Acetate Injection; Lupron Depot PED, 7.5 mg; Lupron Depot PED, 11.25

mg; Lupron Depot PED, 15 mg; Lupron Depot, 3.75 mg; Lupron Depot, 11.25 mg; Lupron Depot 7.5 mg; Lupron Depot, 3 month, 22.5 mg; Lupron Depot, 30 mg; Lupron Depot PED, 11.25 mg, 3 month; Lurpon Depot PED, 3 month, 30 mg; Leuprolide Acetate Prefilled Dual Chamber Syringe (PDS), 45 mg; Leuprorelin Vial, 11.25 mg; Leuprolide Acetate Depot, 22.5 mg vial; Leuprorelin Prefilled Dual-

chambered Syringe, 3.75 mg; Leuprorelin Prefilled Dual-chambered Syringe, 11.25 mg; Leuprorelin Vial, 3.75 mg; Leuprorelin Acetate Prefilled Dual-chambered Syringe, 3.75 mg; Leuprorelin Acetate Prefilled Dual-chambered Syringe, 30 mg; Leuprolide Acetato Depot PDS 30 mg 6 Months; Leuprolide Vial, 3.75 mg; Lupron Depot 6 Month 45 mg PDS Kit; Lupron Depot PDS Kit; Lupron Depot PDS

Kit; Lucrin Depot Kit

Trade name: Lupron; Lucrin; Lupaneta Pack

**List Number:** Prefilled Syringe: 3154; 3306; 3330; 3132; 3662; 3152; 3338; 3680; 3779; 9694;

10511; M316; M346; M920; M922; M923; M924; M925; T016; T017; T052; G752

Kits: 3473; 3641; 3642; 2108; 2282; 2440; 3346; 3663; 3683; G754

Lupaneta Pack kits: 1052; 1053

## 1.2 Relevant identified uses of the substance or mixture and uses advised against

**Recommended use:** Pharmaceuticals

# 1.3 Details of the supplier of the safety data sheet

**Supplier:** AbbVie Inc.

1 North Waukegan Road North Chicago, IL 60064

USA

1-800-255-5162 +1-847-937-7433

**Customer Service Telephone:** 1-800-255-5162 (US and Canada only)

+1-847-937-7433

E-mail Address: AbbVie.SDS@abbvie.com

# 1.4 Emergency telephone number

**Emergency Telephone:** CHEMTREC: 1(800) 424-9300 (in USA and Canada)

or +1-703-527-3887 (international)

# Section 2. Hazards identification

## 2.1 Classification of the substance or mixture

**Regulation (EC) No 1272/2008** 

# Section 2. Hazards identification

**Reproductive toxicity** Category 1B

Classification according to EU Directives 67/548/EEC or 1999/45/EC

**Risk Phrases:** R60 - May impair fertility

R61 - May cause harm to the unborn child

## 2.2 Label elements



Signal Word: Danger

**Hazard Statements:** H360 - May damage fertility or the unborn child

P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container to an approved waste disposal plant

## 2.3 Other hazards

Not determined

# Section 3. Composition/information on ingredients

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Polymers of lactic and glycolic acid	30-80	NA		Not Hazardous*	No data available
Mannitol 69-65-8	10-60	Present		Not Hazardous*	No data available
Leuprolide Acetate 74381-53-6	1-15	NA	R60, R61	Repr. 1B (H360)	No data available
Stearic Acid 57-11-4	0-5	Present		Not Hazardous*	No data available
Carboxymethylcellulose Sodium 9004-32-4	1-5	NA		Not Hazardous*	No data available
Gelatin 9000-70-8	0-5	Present		Not Hazardous*	No data available
Polysorbate 80 9005-65-6	0.1-1	NA		Not Hazardous*	No data available

Section 3. Composition/information on ingredients							
Water	0-1	Present		Not Hazardous*	No data available		
7732-18-5							

Not Hazardous\* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

For the full text of the R-phrases mentioned in this Section, see Section 16

For the full text of the H-Statements mentioned in this Section, see Section 16

# Section 4. First aid measures

## 4.1 Description of first aid measures

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation

persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation

persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Provide symptomatic/supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Provide symptomatic/supportive care as necessary.

**Protection of First-aiders:** Use personal protective equipment

## 4.2 Most important symptoms and effects, both acute and delayed

**Signs and Symptoms:** None known from occupational exposure. Clinical data suggests the following:

variable sex hormone level changes. Clinical signs may include, feeling hot, edema,

gastrointestinal upset, dizziness, headaches, bone and joint pain, weakness.

**Medical Conditions** Data suggest any pre-existing ailments in the following organs: ovaries, testes,

**Aggravated by Exposure:** urinary bladder.

## 4.3 Indication of any immediate medical attention and special treatment needed

**Notes To Physician:** Treat symptomatically

# Section 5. Firefighting measures

#### 5.1 Extinguishing Media

**Suitable Extinguishing Media:** Use extinguishing agent suitable for type of surrounding fire

Unsuitable Extinguishing Media: Not determined

#### 5.2 Special hazards arising from the substance or mixture

**Special Exposure Hazards:** Not determined

# 5.3 Advice for firefighters

**Protective Equipment and Precautions for Firefighters:** 

As in any fire, wear self-contained breathing apparatus and full protective gear

# Section 6. Accidental release measures

# 6.1. Personal precautions, protective equipment and emergency procedures

**Personal Precautions:** For personal protection see section 8

## **6.2.** Environmental precautions

**Environmental Precautions:** Contain material and prevent release to waterways or soil.

# 6.3. Methods and material for containment and cleaning up

Methods for Cleaning Up: Wash spill area with 10% (v/v) bleach, then clean using a detergent solution followed

by clean water.

## 6.4. Reference to other sections

Refer to Sections 8, 12, and 13 for further information.

# Section 7. Handling and storage

## 7.1. Precautions for safe handling

Avoid contact with skin, eyes and clothing. Handle in accordance with good industrial hygiene and safety practice.

# 7.2. Conditions for safe storage, including any incompatibilities

Store according to label instructions

## 7.3. Specific end use(s)

**Recommended use:** Pharmaceuticals

# Section 8. Exposure controls/personal protection

# **8.1.** Control parameters

## **Exposure limits:**

Chemical Name	Employee Exposure Limit	Skin Notation
Polymers of lactic and glycolic acid	Not Applicable	None
Mannitol 69-65-8	Not Applicable	None
Leuprolide Acetate 74381-53-6	0.05 mcg/m <sup>3</sup>	None
Stearic Acid 57-11-4	Not Applicable	None
Carboxymethylcellulose Sodium 9004-32-4	Not Applicable	None
Gelatin 9000-70-8	Not Applicable	None

**Product Name: Lupron Depot** Jun-10-2013 **Issued:** 

Polysorbate 80 9005-65-6	Not Applicable	None
Water 7732-18-5	Not Applicable	None

Chemical Name	ACGIH TLV	France	German MAK	Ireland	Italy
Stearic Acid	10 mg/m <sup>3</sup> for nuisance				
57-11-4	dust; 3 mg/m <sup>3</sup> respirable				
	particulate				
Carboxymethylcellulose Sodium	10 mg/m <sup>3</sup> total dust; 3				
9004-32-4	mg/m³ respirable dust				

# 8.2. Exposure controls

**Engineering Controls:** No special provisions are required under normal product use conditions.

Use inside a process enclosure when handling the bulk formulation.

**Respiratory Protection:** Respiratory protection is not needed during normal product use. When handling the

bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be worn when

exposures are expected to exceed the applicable limits.

**Eyes:** Eye protection not needed during typical product use conditions. Wear eye

protection as appropriate when handling the bulk formulation.

Gloves not required during normal product use conditions. Wear impervious gloves Gloves:

when handling the bulk formulation.

Other PPE Data: Wear appropriate body coverings if contact may occur.

**Environmental Exposure** 

**Controls:** 

Not determined

# Section 9. Physical and chemical properties

#### 9.1. Information on basic physical and chemical properties

Appearance: Syringe powder chamber: White Powder in a Syringe liquid chamber: Clear

> Colorless Solution Not determined.

Odor: **Odor Threshold:** Not determined

5-7 for the reconstituted product.

**Boiling Pt.** @ 760 mm Hg (°C): Not determined. **Melting/Freezing Point (°C):** Not determined Flash Point (°C): Not determined. **Evaporation Rate at 20°C:** Not determined. Flammability (Solid): Not determined. **Lower Explosive Limit:** Not determined. Not determined.

**Upper Explosive Limit: Vapor Pressure (mm Hg):** Not determined. Vapor Density (Air = 1): Not determined. **Specific Gravity:** Not determined. Solubility(ies): Not determined. Partition coefficient: n-

octanol/water

Not determined.

Autoignition Temp. (°C): Not determined.

Decomposition temperature (°C): Not determined.

Viscosity (centipoise): Not determined.

Explosion Severity: Not determined.

Oxidizer Properties: Not determined.

# 9.2. Other information

Not determined

# Section 10. Stability and reactivity

# 10.1. Reactivity

Not determined

# 10.2. Chemical stability

Stable under normal conditions

# 10.3. Possibility of hazardous reactions

**Hazardous reactions:** Not determined.

## 10.4. Conditions to avoid

Not determined.

## 10.5 Incompatible materials

**Hypochlorite Solutions** 

# 10.6 Hazardous decompostion products

Not determined.

# Section 11. Toxicological information

# 11.1. Information on toxicological effects

**Routes of Exposure:** 

Oral: Not determined.

Dermal: Not determined.

Inhalation: Not determined.

**Acute Toxicity - Oral:** Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Mannitol	LD50 =	13,500-22,000	mg/kg	Mice Rats
69-65-8				
Leuprolide Acetate	LD50 >	5000	mg/kg	Mice Rats
74381-53-6				
Stearic Acid	LD50 >	4640	mg/kg	Rats
57-11-4				
Carboxymethylcellulose Sodium	LD50 =	19000	mg/kg	Guinea Pigs
9004-32-4		27000		Mice Rabbits
Polysorbate 80	LD50 =	25,000 - 36,570	mg/kg	Mice Rats
9005-65-6				

**Acute Toxicity - Dermal:** Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species	
Stearic Acid 57-11-4	LD50 >	5000	mg/kg	Rabbits	
Carboxymethylcellulose Sodium 9004-32-4	LD50 >	2000	mg/kg	Rabbits	

**Acute Toxicity - Inhalation:** Data for component (s) given below.

Chemical Name	Test	Value	Units	Species
Carboxymethylcellulose Sodium	LC 50 >	5800	mg/m <sup>3</sup>	Rats
9004-32-4				

**Other Toxicology Data:** Data for component (s) given below:

Chemical Name	Test Type	Value	Units	Species	Comments
Leuprolide Acetate	LD 50 (sc) >	5	mg/kg	Rats Mice	Highly Toxic
74381-53-6	LD 50 (im) >	2	mg/kg	Rats Mice	

**Corrosivity:** Not determined.

**Dermal Irritation:** Not determined.

**Eye Irritation:** Not determined.

**Sensitization:** Not determined.

**Toxicokinetics/Metabolism:** Not determined.

**Target Organ Effects:** Data for component (s) given below.

Chemical Name	Target Organs:	Species	Dosage	Units	Route	Duration
Mannitol 69-65-8	Eyes Kidney	Rats Mice	25,000	ppm	Oral Diet	Repeat dose study (ies).

**Reproductive Effects:** Active Ingredient: In animal and human data, adverse reproductive effects included:

embryo toxicity, fetal abnormalities. In clinical use adverse reproductive effects

include: reduced fertility in males. Data for component (s) given below.

Chemical Name	Species	Dosage	Units	Route	Duration
Leuprolide Acetate	Rabbits	0.1	mcg/kg	Subcutaneous	During Gestation
74381-53-6					•

**Carcinogenicity:** Active ingredient : In animals produced tumors in the following tissue (s): pituitary

gland.

Data for component(s) given below.

Chemical Name	Site of Tumors	Species	Dosage	Route	Units	Duration
Leuprolide Acetate	Pituitary gland	Rats	0.6	Subcutaneous	mg/kg/day	2 years
74381-53-6	No tumors	Mice	60			-

Mutagenicity: Not determined.

**Aspiration hazard:** Not determined

**Notes:** 

1. ALD: Approximate lethal dosage

2. LC50: Concentration in air that produces 50% mortality

3. LD50: Oral or dermal dosage that produces 50% mortality

# Section 12. Ecological information

## 12.1. Toxicity

Not determined.

#### 12.2. Persistence and degradability

Not determined.

#### 12.3. Bioaccumulative potential

Not determined

#### 12.4. Mobility in soil

Not determined.

#### 12.5. Results of PBT or vPvB assessment

Chemical safety report is not required for this substance/product.

## 12.6. Other adverse effects

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

#### **Notes:**

- 1. EC50: Concentration in water that produces 50% mortality in Daphnia sp.
- 2. LC50: Concentration in water that produces 50% mortality in fish.
- 3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

# Section 13. Disposal considerations

#### 13.1 Waste treatment methods

**Waste Disposal Methods:** Disposal should be made in accordance with country, federal, state and local

regulations.

# Section 14. Transport information

#### ADR, DOT, ICAO/IATA, IMDG/IMO

**Status:** Not regulated

14.1. UN Number: Not applicable
14.2. Proper shipping name: Not applicable
14.3. Hazard class: Not applicable
14.4. Packing group: Not applicable
14.5. Environmental hazard: Not applicable
14.6. Special Provisions: Not applicable

**14.7. Transport in bulk according** Not applicable **to Annex II of MARPOL 73/78 and the IBC Code:** 

# Section 15. Regulatory Information

# 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

# **International Inventories**

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Polymers of lactic and glycolic acid	-	-	-	Not listed.	-
Mannitol 69-65-8	Present	X	X	Not listed.	X
Leuprolide Acetate 74381-53-6	-	-	X	Not listed.	-
Stearic Acid 57-11-4	Present	X	X	Not listed.	X
Carboxymethylcellulose Sodium 9004-32-4	-	X	X	Not listed.	X
Gelatin 9000-70-8	Present	X	X	Not listed.	X
Polysorbate 80 9005-65-6	-	X	X	Not listed.	X
Water 7732-18-5	Present	X	X	Not listed.	X

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Polymers of lactic and glycolic acid	-	-	-	-	-	
Mannitol 69-65-8	Present	Present	X	X	Present	
Leuprolide Acetate 74381-53-6	-	-	-	-	-	
Stearic Acid 57-11-4	Present	-	X	X	Present	
Carboxymethylcellulose Sodium 9004-32-4	Present	Present	X	X	Present	HSR003136
Gelatin 9000-70-8	Present	-	X	X	Present	
Polysorbate 80 9005-65-6	Present	-	X	X	Present	
Water 7732-18-5	-	2-(4)-1220	X	X	Present	

## Legend

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

 $\pmb{DSL/NDSL}\ -\ Canadian\ Domestic\ Substances\ List/Non-Domestic\ Substances\ List$ 

PICCS - Philippines Inventory of Chemicals and Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

ISHL - Japan Industrial Safety and Health Law

IECSC - China Inventory of Existing Chemical Substances
AICS - Australian Inventory of Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

## **Carcinogenicity Rating:**

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Polymers of lactic and glycolic acid	30-80	Not Listed	Not Listed	Not Listed

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Mannitol	10-60	Not Listed	Not Listed	Not Listed
Leuprolide Acetate	1-15	Not Listed	Not Listed	Not Listed
Stearic Acid	0-5	Not Listed	Not Listed	Not Listed
Carboxymethylcellulose Sodium	1-5	Not Listed	Not Listed	Not Listed
Gelatin	0-5	Not Listed	Not Listed	Not Listed
Polysorbate 80	0.1-1	Not Listed	Not Listed	Not Listed
Water	0-1	Not Listed	Not Listed	Not Listed

# **SARA 313 Information**

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA	SARA EHS TPQ (lbs):
			EHS RQ (lbs):	
Polymers of lactic and glycolic acid	30-80	No	Not Applicable	Not applicable
Mannitol	10-60	No	Not Applicable	Not applicable
Leuprolide Acetate	1-15	No	Not Applicable	Not applicable
Stearic Acid	0-5	No	Not Applicable	Not applicable
Carboxymethylcellulose Sodium	1-5	No	Not Applicable	Not applicable
Gelatin	0-5	No	Not Applicable	Not applicable
Polysorbate 80	0.1-1	No	Not Applicable	Not applicable
Water	0-1	No	Not Applicable	Not applicable

Immediate Health:YesDelayed Health:NoFire:NoSudden Pressure:NoReactivity:No

**RCRA Status:** Not determined.

**Proposition 65 Status:** Chemicals known to the State of California to cause cancer or reproductive harm

listed below.

Chemical Name	Percent	Proposition 65 Listed Materials
Leuprolide Acetate	1-15	Developmental, female, male. Listed August 1997

WHMIS Hazard Class: Not determined.

## **NFPA Rating:**

Health: 1 Fire: 1 Reactivity: 0

Notes:

- 1. SARA = Superfund Amendments and the Reauthorization Act.
- 2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
- 3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
- 4. TSCA = Toxic Substances Control Act.
- 5. EC = European Community.
- 6. WHMIS = Canadian Workplace Hazardous Materials Information System.
- 7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

# 15.2. Chemical safety assessment

Chemical safety assessment has not been conducted on the substance/product.

# Section 16. Other information

**Risk Phrases:** R60 - May impair fertility, R61 - May cause harm to the unborn child

## Full text of H-Statements referred to under sections 2 and 3

H360 - May damage fertility or the unborn child

**Document Authored By:** Global Occupational Toxicology (D-03QC)

**Issued:** Jun-10-2013

**Supersedes the SDS dated:** Sep-14-2010

#### **Disclaimer:**

The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.